News and Announcements

Edward M. Schaeffer, MD, PhD, outlines Northwestern Medicine's strategic growth in urology and healthcare administration, highlighting partnerships and expansions over the past decade. Under his leadership since 2015, the department has established a robust team of 18 urologists across 8 sites within an 11-hospital system serving Chicagoland, integrating quality standards, education, and marketing to ensure consistent, high-quality care across geographic regions

Patients with metastatic urothelial cancer and increased expression of the NECTIN4 gene had a dramatically better response to antibody treatment than patients with reduced gene expression, according to recent findings published in the Journal of Clinical Oncology.

Joshua Meeks, MD, PhD, and other experts delve into the key takeaways and groundbreaking highlights from the 2024 American Urological Association Annual Meeting. 

Joshua J. Meeks, MD, PhD, provides a comprehensive overview of a session held at the 2024 American Urological Association Annual Meeting titled, "Leveraging Innovation in Bladder Cancer Care: Expert Tactics for Successfully Integrating Contemporary Therapeutic Advances Throughout the Disease Spectrum."

Edward M. Schaeffer, MD, PhD, explores the latest developments and future prospects of PSMA-PET technology in the realm of prostate cancer diagnosis and treatment. With his vast knowledge and scholarly contributions to the field, Dr. Schaeffer provides invaluable insights into the evolving role of PSMA-PET imaging, highlighting its potential to revolutionize the way prostate cancer is detected, staged, and managed. 

Amy Krambeck, MD, delves into the complexities of kidney stone formation and recurrence, emphasizing the pivotal role dietary changes play in mitigating risks. Amidst the plethora of advice on what to avoid, she highlights key dietary habits that can proactively prevent the onset of kidney stones.

Joshua Meeks, MD, PhD, discuss the ongoing BCG shortage affecting bladder cancer treatment, tracing its roots to production issues in 2012 and increased demand following guideline changes in 2016. He highlight the growing use of Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its availability and proven effectiveness. The conversation also explores the BRIDGE trial, a critical study evaluating the efficacy of Gem/Doce, as well as several large trials investigating checkpoint inhibitors as potential alternatives to BCG.

Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how to sneakily use that to destroy it.

Robert Brannigan, MD, Kristin Smith, and Joshua A. Halpern, MD, MS, engage in a comprehensive discussion regarding the innovative oncofertility program at Northwestern University. As pioneers in the field, Dr. Brannigan and his esteemed colleagues shed light on the multidisciplinary approach adopted by the program, which aims to address the unique reproductive concerns of cancer patients. Through their expertise in urology, oncology, and reproductive endocrinology, they explore the latest advancements and personalized strategies for preserving fertility in individuals undergoing cancer treatment. 

Adam Murphy, MD, MBA, MSCI, discusses the heightened risk of prostate cancer among Black men. Dr. Murphy delves into the various factors contributing to this increased vulnerability, such as genetic predispositions, socioeconomic disparities, and healthcare access issues. Dr. Murphy emphasizes the importance of addressing these factors to reduce the disproportionate impact of prostate cancer on Black men and advocates for tailored strategies in screening, prevention, and treatment.

In the wake of public figures like Lloyd Austin and Ryne Sandberg confronting the challenges of prostate cancer, Shailajit Kundu, MD, takes part in an insightful conversation with NBC Chicago's Lauren Petty to provides a comprehensive exploration of the complexities surrounding prostate cancer. Dr. Kundu discusses the advancements in treatment of prostate cancer, the importance of early detection, and the impact on both patients and their communities. 

In the discussion about the management of low-risk prostate cancer through active surveillance, Dr. Catalona undergoes a notable shift in perspective.  Initially opposed to active surveillance, he has since adjusted his views, preferring a more conservative approach. This discussion centers on this shift in mindset and its impact on the approach to active surveillance in low-risk prostate cancer cases.